Journal article

Trans-ethnic genome-wide association study of colorectal cancer identifies a new susceptibility locus in VTI1A

Hansong Wang, Terrilea Burnett, Suminori Kono, Christopher A Haiman, Motoki Iwasaki, Lynne R Wilkens, Lenora WM Loo, David Van den Berg, Laurence N Kolonel, Brian E Henderson, Temitope O Keku, Robert S Sandler, Lisa B Signorello, William J Blot, Polly A Newcomb, Mala Pande, Christopher I Amos, Dee W West, Stephane Bezieau, Sonja I Berndt Show all

NATURE COMMUNICATIONS | NATURE PUBLISHING GROUP | Published : 2014

Grants

Awarded by US National Institutes of Health (NIH)


Awarded by NIH


Awarded by Department of Defense Breast Cancer Research Program, Era of Hope Scholar Award


Awarded by Center for Clinical and Translational Sciences of the University of Texas Health Science Center at Houston, NCI Cancer Center Support Grant


Awarded by NCI


Awarded by National Cancer Institute as part of the GAME-ON consortium


Awarded by National Human Genome Research Institute at the NIH


Awarded by National Institute of Environmental Health Sciences at the NIH


Awarded by National Cancer Institute, NIH under RFA


Awarded by National Cancer Institute


Awarded by Australasian Colorectal Cancer Family Registry


Awarded by Seattle Colorectal Cancer Family Registry


Awarded by Ontario Registry for Studies of Familial Colorectal Cancer


Awarded by German Research Council (Deutsche Forschungsgemeinschaft)


Awarded by German Federal Ministry of Education and Research


Awarded by NHS by the NIH


Awarded by PHS by the NIH


Awarded by NIH, Genes, Environment and Health Initiative (GEI)


Awarded by NIH GEI


Awarded by NIH.


Awarded by The NIH



Awarded by NATIONAL CANCER INSTITUTE


Awarded by NATIONAL HUMAN GENOME RESEARCH INSTITUTE


Awarded by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES


Awarded by NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES


Funding Acknowledgements

We thank Dr Daniel Mirel, who supervised the genotyping of samples while working at the Broad Institute, Boston, MA, and Xin Sheng, Loreall Pooler, Dr Gary K. Chen and Alex H. Stram at the University of Southern California (USC), and Lucy Shen and Mike Loomis at the University of Hawai'i Cancer Center for their technical assistance. The colorectal cancer GWAS among Japanese and African Americans was funded through US National Institutes of Health (NIH) grants 1R01-CA126895, 1R01-CA126895-S1, 1R01-CA104132 and 2U24-CA074806. Genotyping of the additional MEC controls was funded through NIH grants R01-CA132839, RC2-CA148085, R01-CA1326792 and U01-HG004726, as well as a Department of Defense Breast Cancer Research Program, Era of Hope Scholar Award to CAH (W81XWH-08-1-0383). MEC was funded through NIH grants R37 CA54281, P01 CA033619, and R01 CA63464. The SCCS was funded by NIH grant R01CA092447. Data on SCCS cancer cases used in this publication were provided by the Alabama Statewide Cancer Registry; Kentucky Cancer Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer Surveillance; Florida Cancer Data System; North Carolina Central Cancer Registry, North Carolina Division of Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry; Virginia Department of Health, Virginia Cancer Registry; Arkansas Department of Health, Cancer Registry, 4815 W. Markham, Little Rock, AR 72205. The Arkansas Central Cancer Registry is fully funded by a grant from National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC). Data on SCCS cancer cases from Mississippi were collected by the Mississippi Cancer Registry, which participates in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Mississippi Cancer Registry. The UNC studies were supported by grants U01 CA 093326, P50 CA 106991 and R01 CA 66635. The MD Anderson data collection was supported in part by the MD Anderson University Cancer Fund, the MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment, the Center for Clinical and Translational Sciences of the University of Texas Health Science Center at Houston, NCI Cancer Center Support Grant (CA16672) and NCI grant (K07CA160753). JPHC was supported by the National Cancer Center Research and Development Fund (since 2011) and a Grant-in-Aid for Cancer Research (from 1989 to 2010) from the Ministry of Health, Labor and Welfare of Japan. The Fukuoka Colorectal Cancer Study was funded by the Ministry of Education, Culture, Sports, Science and Technology, Japan. The CORECT Study is supported by the National Cancer Institute as part of the GAME-ON consortium (U19 CA148107) with additional support from NCI grants (R01 CA81488, P30 CA014089), the National Human Genome Research Institute at the NIH (T32 HG000040) and the National Institute of Environmental Health Sciences at the NIH (T32 ES013678). CCFR (http://www.coloncfr.org/) is supported by the National Cancer Institute, NIH under RFA # CA-95-011 and through cooperative agreements with members of the Colon Cancer Family Registry and PIs of the Australasian Colorectal Cancer Family Registry (U01 CA097735), Familial Colorectal Neoplasia Collaborative Group (U01 CA074799) [USC], Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01 CA074800), Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783), Seattle Colorectal Cancer Family Registry (U01 CA074794) and the University of Hawaii Colorectal Cancer Family Registry (U01 CA074806). The Colon CFR GWAS work was supported by a National Cancer Institute grant (U01CA122839 and P30 CA014089), Australasian Colorectal Cancer Family Registry (U01 CA097735), Seattle Colorectal Cancer Family Registry (U01 CA074794) and Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute, NIH or any of the collaborating centres in the CCFRs, nor does it mention trade names, commercial products or organizations imply endorsement by the US Government or the CCFR. GECCO was funded by NIH grants U01 CA137088 and R01 CA059045. ASTERISK was supported by a Hospital Clinical Research Program (PHRC) and by the Regional Council of Pays de la Loire, the Groupement des Entreprises Francaises dans la Lutte contre le Cancer (GEFLUC), the Association Anne de Bretagne Genetique and the Ligue Regionale Contre le Cancer (LRCC). CR2&3 was funded by NIH grant R01 CA60987. DACHS was funded by the German Research Council (Deutsche Forschungsgemeinschaft, BR 1704/6-1, BR 1704/6-3, BR 1704/6-4 and CH 117/1-1) and the German Federal Ministry of Education and Research (01KH0404 and 01ER0814). DALS was funded by the NIH (R01 CA48998 to M. L. S.). HPFS is supported by the NIH (P01 CA 055075, UM1 CA167552, R01 137178, and P50 CA 127003), NHS by the NIH (R01 CA137178, P01 CA 087969 and P50 CA 127003) and PHS by the NIH (R01 CA042182). OFCCR was supported by the NIH through funding allocated to the Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783); see the CCFR section above. As a subset of ARCTIC, OFCCR is supported by a GL2 grant from the Ontario Research Fund, the Canadian Institutes of Health Research, and the Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society Research Institute. Thomas J. Hudson and Brent W. Zanke are recipients of Senior Investigator Awards from the Ontario Institute for Cancer Research, through generous support from the Ontario Ministry of Research and Innovation. PLCO (http://dcp.cancer.gov/plco) was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH. Additionally, a subset of control samples were genotyped as part of the Cancer Genetic Markers of Susceptibility (CGEMS) Prostate Cancer GWAS<SUP>22</SUP>, CGEMS pancreatic cancer scan (PanScan)<SUP>23,24</SUP> and the Lung Cancer and Smoking study<SUP>25</SUP>. The prostate and PanScan study data sets were accessed with appropriate approval through the dbGaP online resource (http://cgems.cancer.gov/data/) accession numbers phs000207.v1.p1 and phs000206.v3.p2, respectively, and the lung data sets were accessed from the dbGaP website (http://www.ncbi.nlm.nih.gov/gap) through accession number phs000093.v2.p2.Funding for the Lung Cancer and Smoking study was provided by NIH, Genes, Environment and Health Initiative (GEI) Z01 CP 010200, NIH U01 HG004446 and NIH GEI U01 HG 004438. For the lung study, the GENEVA Coordinating Center provided assistance with genotype cleaning and general study coordination, and the Johns Hopkins University Center for Inherited Disease Research conducted genotyping. PMH was funded by the NIH grant R01 CA076366 to P. A. Newcomb. NHS was supported by NIH grants CA 087969, R01 137178, and P50 CA 127003. VITAL was funded by NIH grant K05 CA154337. The WHI program is funded by the National Heart, Lung, and Blood Institute, and NIH through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C and HHSN271201100004C. The ASTERISK study are very grateful to Dr Bruno Buecher, without whom this project would not have existed and also thank all those who agreed to participate in this study, including the patients and the healthy control persons, as well as all the physicians, technicians and students. The DACHS study thank all participants and cooperating clinicians, and Ute Handte-Daub, Renate Hettler-Jensen, Utz Benscheid, Muhabbet Celik and Ursula Eilber at DACHS for excellent technical assistance. GECCO would like to thank all those at the Coordinating Center for helping to bring together the data and people that made this project possible. HPFS, NHS and PHS would like to acknowledge Patrice Soule and Hardeep Ranu of the Dana Farber Harvard Cancer Center High-Throughput Polymorphism Core who assisted in the genotyping for NHS, HPFS, and PHS under the supervision of Dr Immaculata Devivo and Dr David Hunter, Qin (Carolyn) Guo and Lixue Zhu who assisted in programming for NHS and HPFS, and Haiyan Zhang who assisted in programming for the PHS. We would like to thank the participants and staff of the Nurses' Health Study and the Health Professionals Follow-Up Study, for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA and WY. In addition, this study was approved by the Connecticut Department of Public Health (DPH) Human Investigations Committee. Certain data used in this publication were obtained from the DPH. The authors assume full responsibility for analyses and interpretation of these data. The PLCO thank Drs Christine Berg and Philip Prorok, Division of Cancer Prevention, National Cancer Institute, the Screening Center investigators and staff of the PLCO Cancer Screening Trial, Mr. Tom Riley and staff, Information Management Services, Inc., Ms. Barbara O'Brien and staff, Westat, Inc., and Drs Bill Kopp, Wen Shao, and staff, SAIC-Frederick, and most importantly the study participants for their contributions to making this study possible. The PMH study would like to thank the study participants and staff of the Hormones and Colon Cancer study. The WHI study thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: https://cleo.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Short%20List.pdf.